Tags

Type your tag names separated by a space and hit enter

Baicalein reduces inflammatory process in a rodent model of diabetic retinopathy.
Invest Ophthalmol Vis Sci. 2009 May; 50(5):2319-27.IO

Abstract

PURPOSE

This study was designed to elucidate the role of inflammatory process in diabetic retinopathy and to investigate the effect of baicalein treatment on diabetic rat.

METHODS

Retinal microglial cells were identified with CD11b antibody, and retinal Müller cells were identified with glial fibrillary acidic protein (GFAP). The gene expression of interleukin (IL)-18, tumor necrosis factor (TNF)-alpha, and IL-1beta was examined by quantitative real-time PCR. The expression of GFAP and vascular endothelial growth factor (VEGF) was examined by quantitative real-time PCR, immunohistochemistry, and Western blot analysis. Vascular permeability was measured in vivo by bovine serum albumin conjugated with FITC. Baicalein was given by oral administration (150 mg/kg/d) with an animal feeding needle beginning 5 days after streptozotocin (STZ) injection.

RESULTS

By 24 weeks after onset of diabetes, microglial cells were activated and proliferated, and Müller cells upregulated their GFAP and VEGF expression. Pro-inflammatory factors, including IL-18, TNF-alpha, and IL-1beta, were significantly upregulated. Obvious vascular leakage and abnormality were demonstrated, and ganglion cell loss was significant. Baicalein treatment ameliorated diabetes-induced microglial activation and pro-inflammatory expression, reduced the GFAP and VEGF expression from Müller cells, and significantly reduced vascular abnormality and ganglion cell loss within the retina.

CONCLUSIONS

Inflammatory process, characterized by microglial activation and Müller cells dysfunction, was implicated in STZ-induced diabetic retinopathy. Baicalein treatment ameliorated inflammatory process, and therefore inhibited vascular abnormality and neuron loss in diabetic retinas.

Authors+Show Affiliations

Peking University Eye Center, Peking University Third Hospital, Peking University, Beijing, PR China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19011009

Citation

Yang, Li-ping, et al. "Baicalein Reduces Inflammatory Process in a Rodent Model of Diabetic Retinopathy." Investigative Ophthalmology & Visual Science, vol. 50, no. 5, 2009, pp. 2319-27.
Yang LP, Sun HL, Wu LM, et al. Baicalein reduces inflammatory process in a rodent model of diabetic retinopathy. Invest Ophthalmol Vis Sci. 2009;50(5):2319-27.
Yang, L. P., Sun, H. L., Wu, L. M., Guo, X. J., Dou, H. L., Tso, M. O., Zhao, L., & Li, S. M. (2009). Baicalein reduces inflammatory process in a rodent model of diabetic retinopathy. Investigative Ophthalmology & Visual Science, 50(5), 2319-27. https://doi.org/10.1167/iovs.08-2642
Yang LP, et al. Baicalein Reduces Inflammatory Process in a Rodent Model of Diabetic Retinopathy. Invest Ophthalmol Vis Sci. 2009;50(5):2319-27. PubMed PMID: 19011009.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Baicalein reduces inflammatory process in a rodent model of diabetic retinopathy. AU - Yang,Li-ping, AU - Sun,Hui-li, AU - Wu,Le-meng, AU - Guo,Xiu-juan, AU - Dou,Hong-liang, AU - Tso,Mark O M, AU - Zhao,Lin, AU - Li,Shun-min, Y1 - 2008/11/14/ PY - 2008/11/18/pubmed PY - 2009/5/13/medline PY - 2008/11/18/entrez SP - 2319 EP - 27 JF - Investigative ophthalmology & visual science JO - Invest Ophthalmol Vis Sci VL - 50 IS - 5 N2 - PURPOSE: This study was designed to elucidate the role of inflammatory process in diabetic retinopathy and to investigate the effect of baicalein treatment on diabetic rat. METHODS: Retinal microglial cells were identified with CD11b antibody, and retinal Müller cells were identified with glial fibrillary acidic protein (GFAP). The gene expression of interleukin (IL)-18, tumor necrosis factor (TNF)-alpha, and IL-1beta was examined by quantitative real-time PCR. The expression of GFAP and vascular endothelial growth factor (VEGF) was examined by quantitative real-time PCR, immunohistochemistry, and Western blot analysis. Vascular permeability was measured in vivo by bovine serum albumin conjugated with FITC. Baicalein was given by oral administration (150 mg/kg/d) with an animal feeding needle beginning 5 days after streptozotocin (STZ) injection. RESULTS: By 24 weeks after onset of diabetes, microglial cells were activated and proliferated, and Müller cells upregulated their GFAP and VEGF expression. Pro-inflammatory factors, including IL-18, TNF-alpha, and IL-1beta, were significantly upregulated. Obvious vascular leakage and abnormality were demonstrated, and ganglion cell loss was significant. Baicalein treatment ameliorated diabetes-induced microglial activation and pro-inflammatory expression, reduced the GFAP and VEGF expression from Müller cells, and significantly reduced vascular abnormality and ganglion cell loss within the retina. CONCLUSIONS: Inflammatory process, characterized by microglial activation and Müller cells dysfunction, was implicated in STZ-induced diabetic retinopathy. Baicalein treatment ameliorated inflammatory process, and therefore inhibited vascular abnormality and neuron loss in diabetic retinas. SN - 1552-5783 UR - https://www.unboundmedicine.com/medline/citation/19011009/Baicalein_reduces_inflammatory_process_in_a_rodent_model_of_diabetic_retinopathy_ L2 - https://iovs.arvojournals.org/article.aspx?doi=10.1167/iovs.08-2642 DB - PRIME DP - Unbound Medicine ER -